Woodstock, GA, August 24, 2012 -- TISSUE REGENERATION TECHNOLOGIES, LLC today announced that that the U.S. Patent and Trademark Office will issue the Company patent number 8257282 on September 4, 2012. The patent will cover an apparatus for generating pressure pulse/shock waves utilizing TRT’s unfocused, Softwave™ technology.
The patent will comprise shock wave fronts having plane, nearly plane, convergent off target and/or divergent characteristics, and thus will embody a wide range of unfocused shock wave technologies and utilizations.
John Warlick, CEO of TRT, described the patent issuance’s importance on the company’s ever-expanding intellectual property portfolio. “This latest patent is critically important to TRT and a milestone in that it will protect our unfocused shock wave – Softwave™ – franchise,” he said. “This broad patent for our unfocused technology for the treatment of tissue is invaluable in helping to develop and protect our Softwave™ technology.”
Woodstock, GA, April 24, 2012 – Tissue Regeneration Technologies, LLC (TRT) today announced that the US patent and Trademark office (USPTO) has issued the company patent number US 8,162,859, titled “Shock Wave Treatment Device and Method of Use”. The patent relates to a side firing, sterile, disposable, hand held probe used in the direct application of shock waves to Ischemic Heart Tissue. TRT, with its cardiology affiliate Cardio Regeneration Technologies (CRT), is the first company worldwide to apply shock waves directly to the human heart. After exhaustive animal studies to establish safety, 10 patients with scarred heart tissue, post-heart attack, were treated with the patented device at the University of Vienna. After treatment, there was strong statistically significant evidence proving substantially improved heart function and quality of life measures. Phase II Trials are now scheduled to begin at the University of Innsbruck, Innsbruck, Austria.
Tissue Regeneration Technologies awarded new patents for biofilm elimination and reproductive health
August 25, 2010 (Woodstock, Georgia) – Tissue Regeneration Technologies, LLC (TRT), a Woodstock, GA based medical technology company, recently received the rights to two new patents for its SoftWave™ technology portfolio.
The two patents, a method of preventing and eliminating biofilms (U.S. Patent No. 7,497,834) and a therapeutic stimulation of genital tissue to combat infertility or impotence (U.S. Patent No. 7,601,127), exemplify the growth and expansion of TRT's SoftWave™ technology.
August 25, 2010 (Woodstock, Georgia) – Tissue Regeneration Technologies, LLC (TRT), a Woodstock, Georgia medical technology company, recently received the rights to a new patent to bolster its SoftWave™ technology portfolio. The patent covers a method of reattaching damaged soft tissue to bone.
Surgical procedures of reattaching damaged tissues such as ligaments and tendons to bone typically involve sutures or screws, and success is not guaranteed. Transplant cadaver ligaments are used when a person's own are unlikely to reattach under normal surgical procedures. Furthermore, time is of the essence in such procedures; generally, more time elapsed before or after operation results in lower success rates.
TRT's new patent (U.S. Patent No. 7,594,930) involves administering shock waves to a surgically anchored tissue in order to increase procedure reliability and decrease healing time. The new method is effective with either a patient's own or transplant tissues. The treatment is used whenever a ligament or muscle detaches from bone, typically because of severe traumatic injury.
Tissue Regeneration Technologies, LLC awarded another patent to expand its SoftWave™ technology portfolio.
WOODSTOCK, GA. -- Tissue Regeneration Technologies, LLC (TRT), a Woodstock, GA. based medical technology company, announced Monday it received another patent award to expand its innovative unfocused shock wave technology portfolio.
The company’s newest patent award (U.S. Patent 7,695,443) covers a novel device for generating shock waves. TRT’s patent portfolio increases to 15 granted patents and 20 published patent applications. TRT retains rights to its expanding intellectual property portfolio as an exclusive owner and exclusive licensee.
John Warlick, Chief Executive Officer of TRT, stated the recent patent award is aimed at further increasing the effectiveness and reliability of its SoftWave™– unfocused shock wave– technologies.